Equities
Health CareMedical Equipment and Services
  • Price (EUR)1.62
  • Today's Change0.055 / 3.51%
  • Shares traded5.50k
  • 1 Year change+18.68%
  • Beta0.1792
Data delayed at least 15 minutes, as of Mar 05 2026 08:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nanorepro AG is a Germany-based company active in the biotechnology sector. The Company is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patients’ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.

  • Revenue in EUR (TTM)5.13m
  • Net income in EUR-1.72m
  • Incorporated2007
  • Employees21.00
  • Location
    NanoRepro AGUntergasse 8MARBURG AN DER LAHN 35037GermanyDEU
  • Phone+49 6 421951449
  • Fax+49 6 421951451
  • Websitehttps://www.nanorepro.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bio-Gate AG6.98m-1.38m5.50m46.00--6.03--0.7881-0.1522-0.15220.77460.09871.631.8418.31158,615.20-33.43-27.70-46.89-39.9157.7258.42-20.56-20.590.5521-22.330.00---2.6615.13-0.0006---13.98--
ifa systems AG5.88m-570.00k6.38m47.00--0.91924.821.09-0.2073-0.20732.142.500.557611.876.94125,000.00-5.411.67-6.452.2088.2486.82-9.703.222.37--0.000.0015.46-6.8694.40------
Geratherm Medical AG13.65m1.75m14.13m144.009.330.67824.271.040.27990.27992.533.850.4461.266.2488,038.135.903.256.994.0042.0265.0913.225.032.35--0.112989.33-33.29-6.77-36.545.26-22.71-16.74
NanoRepro AG5.13m-1.72m20.19m21.00--0.5293--3.94-0.1336-0.13360.39722.960.13192.8214.52222,860.40-4.4410.32-4.4811.1759.3635.67-33.639.2830.20--0.0040.0140.4229.6956.34---10.11--
aap Implantate AG11.99m-3.72m21.63m90.00--2.18--1.80-0.2564-0.25640.96350.67450.72030.08464.84128,914.00-22.37-25.30-28.83-34.1245.0788.35-31.06-45.191.24-7.740.056--6.320.778354.41---27.86--
EasyMotionSkin Tec GmbH-100.00bn-100.00bn44.02m17.00-------------------------------------------------61.33---384.29------
MeVis Medical Solutions AG16.06m3.17m45.50m102.0014.372.5513.732.831.741.748.829.790.6134--8.55157,463.4012.0917.8315.7124.0497.7097.0919.7129.27----0.0034.61-5.36-1.28-30.58-11.116.490.00
Data as of Mar 05 2026. Currency figures normalised to NanoRepro AG's reporting currency: Euro EUR

Institutional shareholders

10.05%Per cent of shares held by top holders
HolderShares% Held
TBF Global Asset Management GmbHas of 31 Dec 2025942.71k7.31%
SIGNAL IDUNA Asset Management GmbHas of 31 Dec 2025258.00k2.00%
Aramea Asset Management AGas of 31 Dec 202595.63k0.74%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.